ClinicalTrials.gg
CompletedNCT00308308Updated Oct 16, 2014Results posted

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

A Phase 3 interventional study of Technosphere Insulin and Active comparator in Diabetes, Type I, sponsored by Mannkind Corporation. Completed at 129 sites in 10 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
589
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
2nd of 35
589 · median 74
Started
2006
with 3 others
Phase 3
17 of 35
none open now
Registered
2nd of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 4 that started in 2006, is one of 17 in phase 3, and was the 2nd registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes

03

Conditions studied

  • Diabetes, Type I
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of type 1 diabetes for at least 1 year
  • Nonsmokers for prior 6 months
  • less than or equal to 35kg/m2
  • > or = 7% and \< or = 11%
  • Serum creatinine \< or = 1.8 mg/dL in female subjects and \< or = 2.0 mg/dL in male subjects
  • > or = 70% of predicted, DLco > or = 70% , TLC > or = 80% predicted
  • Maintenance of a treatment regimen of insulin less than or equal to 1.4 iu/kg/day
  • Urine cotinine \< or = 100 ng/mL

Exclusion criteria

Exclusion Criteria:

  • History of , asthma, any other pulmonary disease confirmed by documented history, pulmonary function testing or radiologic findings
  • Evidence of severe complications of diabetes
  • Aminotransferase and/or > than 3 times the
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
589 participants (actual)

Study arms

  • Experimental
    1

    Technosphere Insulin

    Drug: Technosphere Insulin

  • Active comparator
    2

    Rapid-acting analogue insulin plus basal insulin glargine

    Drug: Active comparator

Interventions

06

What researchers measure

Primary outcomes

  1. Compare the Mean Change From Baseline to Week 52 in HbA1c

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in Weight to Week 52

    Change from baseline in weight at Week 52

    Time frame: Baseline to Week 52

  2. Change From Baseline in Fasting Plasma Glucose to Week 52

    Change from baseline in fasting plasma glucose at Week 52

    Time frame: Baseline to Week 52

  3. Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%

    Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%

    Time frame: Baseline to Week 52

  4. Incidence of Total Hypoglycemia

    Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.

    Time frame: Baseline to Week 52

  5. Incidence of Severe Hypoglycemia

    Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.

    Time frame: Baseline to Week 52

  6. Total Hypoglycemia Event Rate

    Number of Hypoglycemic Events/Total Subject Exposure Time (in months)

    Time frame: Baseline to Week 52

  7. Severe Hypoglycemia Event Rate

    Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)

    Time frame: Baseline to Week 52

07

Results

Posted Oct 16, 2014

Participant flow

First Patient enrolled Feb, 2006 Multi-national trial conducted in US, Canada, Mexico, Brazil, Argentina, Chile, Spain, UK, Poland, Russia

Participant flow — Overall Study
MilestoneTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Started301288
Completed198220
Not completed10368
Withdrew: Adverse event172
Withdrew: Lost to follow-up55
Withdrew: Physician decision157
Withdrew: Protocol violation314
Withdrew: Withdrawal by subject4719
Withdrew: Various75
Withdrew: Randomized but not dosed816
Withdrew: Other10

Outcome measures

PrimaryCompare the Mean Change From Baseline to Week 52 in HbA1c
Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Percentage
Compare the Mean Change From Baseline to Week 52 in HbA1c
PercentageTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Compare the Mean Change From Baseline to Week 52 in HbA1c-0.13 ± 0.058-0.37 ± 0.059
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · ANCOVA · Mean difference (final values): 0.24 · 95% CI 0.08 to 0.40
SecondaryChange From Baseline in Weight to Week 52

Change from baseline in weight at Week 52

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · kilogram
Change From Baseline in Weight to Week 52
kilogramTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Change From Baseline in Weight to Week 52-0.5 ± 0.321.4 ± 0.30
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (net): -1.8 · 95% CI -2.7 to -1.0
SecondaryChange From Baseline in Fasting Plasma Glucose to Week 52

Change from baseline in fasting plasma glucose at Week 52

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · mg/dl
Change From Baseline in Fasting Plasma Glucose to Week 52
mg/dlTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Change From Baseline in Fasting Plasma Glucose to Week 52-46.5 ± 5.61-25.7 ± 5.23
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · ANCOVA · p = 0.0052 · Mean difference (net): -20.9 · 95% CI -35.4 to -6.3
SecondaryNumber of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%

Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%

Time frame:
Baseline to Week 52
Reported as:
Number · Participants
Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%
ParticipantsTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%3335
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · Regression, Logistic · p = 0.8311 · Odds ratio (or): 0.941 · 95% CI 0.536 to 1.652
SecondaryIncidence of Total Hypoglycemia

Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Incidence of Total Hypoglycemia
percentage of participantsTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Incidence of Total Hypoglycemia85.6792.28
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · Regression, Logistic · p = 0.0124 · Odds ratio (or): 0.488 · 95% CI 0.278 to 0.856Model: Treatment + Site
SecondaryIncidence of Severe Hypoglycemia

Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Incidence of Severe Hypoglycemia
percentage of participantsTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Incidence of Severe Hypoglycemia32.0836.40
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · Regression, Logistic · p = 0.2786 · Odds ratio (or): 0.825 · 95% CI 0.582 to 1.169Model: Treatment + Site
SecondaryTotal Hypoglycemia Event Rate

Number of Hypoglycemic Events/Total Subject Exposure Time (in months)

Time frame:
Baseline to Week 52
Reported as:
Number · Number of events/subject-month
Total Hypoglycemia Event Rate
Number of events/subject-monthTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Total Hypoglycemia Event Rate1.811.86
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · Generalized Estimation Equation · p = 0.1193* Based on Poisson distribution * Model: Treatment + Time Period
SecondarySevere Hypoglycemia Event Rate

Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)

Time frame:
Baseline to Week 52
Reported as:
Number · Number of events/subject-month
Severe Hypoglycemia Event Rate
Number of events/subject-monthTI + Insulin GlargineInsulin Aspart + Insulin Glargine
Severe Hypoglycemia Event Rate0.080.10
Statistical analysis
  • TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine · Generalized Estimating Equation · p = 0.2131* Based on Poisson distribution * Model: Treatment + Time Period

Adverse events

Collected over From first dose to 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TI + Insulin Glargine—52/293 (17.7%)265/293 (90.4%)
Insulin Aspart + Insulin Glargine—47/272 (17.3%)257/272 (94.5%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventTI + Insulin GlargineInsulin Aspart + Insulin Glargine
HypoglycaemiaMetabolism and nutrition disorders30/29334/272
Loss of consciousnessNervous system disorders8/2937/272
Diabetic ketoacidosisMetabolism and nutrition disorders5/2930/272
Hypoglycaemic seizureMetabolism and nutrition disorders2/2934/272
KetoacidosisMetabolism and nutrition disorders3/2930/272
Ankle fractureInjury, poisoning and procedural complications1/2932/272
Gastrooesophageal reflux diseaseGastrointestinal disorders0/2932/272
Road traffic accidentInjury, poisoning and procedural complications1/2932/272
Acute myocardial infarctionCardiac disorders0/2931/272
Angina pectorisCardiac disorders0/2931/272
Most frequent other events
Most frequent other events
EventTI + Insulin GlargineInsulin Aspart + Insulin Glargine
HypoglycaemiaMetabolism and nutrition disorders252/293252/272
CoughRespiratory, thoracic and mediastinal disorders98/29321/272
Upper respiratory tract infectionInfections and infestations46/29341/272
NasopharyngitisInfections and infestations37/29338/272
InfluenzaInfections and infestations23/29319/272
HeadacheNervous system disorders16/29315/272
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders16/2936/272
Pulmonary function test decreasedInvestigations16/2934/272

Baseline characteristics

ITT Population (589 were randomized - 24 Subjects randomized but never dosed)

Age, Continuous
Age, Continuous(years)TI + Insulin GlargineInsulin Aspart + Insulin GlargineTotal
Mean37.9 ± 13.0638.1 ± 13.1838 ± 13.11
Sex: Female, Male
Sex: Female, Male(Participants)TI + Insulin GlargineInsulin Aspart + Insulin GlargineTotal
Female139132271
Male154140294
HbA1c
HbA1c(percent)TI + Insulin GlargineInsulin Aspart + Insulin GlargineTotal
Mean8.4 ± 0.958.5 ± 0.978.5 ± 0.96
Weight
Weight(kilogram)TI + Insulin GlargineInsulin Aspart + Insulin GlargineTotal
Mean76.7 ± 15.6476.8 ± 14.9576.7 ± 15.3
08

Study locations

129 sites
  • Coastal Clinical Research Inc
    Mobile, Alabama 36608, United States
  • Radiant Research (Phoenix)
    Chandler, Arizona 85225, United States
  • International Clinical Research Network
    Chula Vista, California 91911, United States
  • Family Medical Center
    Foothill Ranch, California 92610, United States
  • Diabetes/Lipid Management and Research Center
    Huntington Beach, California 92648, United States
  • South Bay Clinical Research
    Inglewood, California 90301, United States
  • Radiant Research
    San Diego, California 92123, United States
  • Coastal Biomedical Research Inc
    Santa Monica, California 90404, United States
  • Diabetes Research Center
    Tustin, California 92780, United States
  • International Research Associates LLC
    Miami, Florida 33156, United States
  • Laureate Clinical Research Group
    Atlanta, Georgia 30308, United States
  • Atlanta Pharmaceutical Research Center
    Dunwoody, Georgia 30338, United States
  • North Atlanta Endocrinology & Diabetes PC
    Lawrenceville, Georgia 30045, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • John H Stoger Jr Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Clintell Inc
    Skokie, Illinois 60076, United States
  • Medical Research of Louisiana
    Metairie, Louisiana 70002, United States
  • Oschner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • James A Dicke MDPA
    Towson, Maryland 21204, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • Michigan Institute of Medicine
    Livonia, Michigan 48152, United States
  • KMED Research
    St Clair Shores, Michigan 48081, United States
  • Radiant Research Inc (Minneapolis)
    Edina, Minnesota 55435, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Center for Urologic Clinical Trials University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Healthcare Research
    Florissant, Missouri 63031, United States
  • MedEx Healthcare Research Inc(009)
    St Louis, Missouri 63117, United States
  • Amin Radparvar's Private Practice
    St Peters, Missouri 63376, United States
  • Billings Clinic Research Division
    Billings, Montana 59101, United States
  • Creighton Diabetes Center
    Omaha, Nebraska 68131, United States
  • University of New Mexico HCS
    Albuquerque, New Mexico 87131, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • North Shore Diabetes and Endocrine Associates
    New Hyde Park, New York 11042, United States
  • University of Physicians Group Endocrine Division
    Staten Island, New York 10301, United States
  • Endocrine Research - Physician's East PA
    Greenville, North Carolina 27834, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Providence Health Partners - Center of Clinical Research
    Dayton, Ohio 45439, United States
  • Portland Diabetes & Endocrinology Center
    Portland, Oregon 97210, United States
  • Legacy Clinical Research
    Portland, Oregon 97232, United States
  • Covance CRU Inc.
    Portland, Oregon 97239, United States
  • Pennsylvania Research Institute
    Bensalem, Pennsylvania 19020, United States
  • Southeastern Research Associates Inc
    Williamston, South Carolina 29697, United States
  • AM Diabetes and Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • The Endocrine Clinic
    Memphis, Tennessee 38119, United States
  • Israel Hartman MD
    Arlington, Texas 76014, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230, United States
  • Radiant Research Dallas-North
    Dallas, Texas 75231, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Spuhler Medical Associates
    Friendswood, Texas 77546, United States
  • Quality Assurance Research Center (900)
    San Antonio, Texas 78205, United States
  • Diabetes & Glandular Disease Research Assoc PA
    San Antonio, Texas 78229, United States
  • SAM Clinical Research Center
    San Antonio, Texas 78229, United States
  • Edward Bali MD PA
    Seguin, Texas 78155, United States
  • Radiant Research Salt Lake City
    Salt Lake City, Utah 84107, United States
  • Salt Lake Research
    Salt Lake City, Utah 84107, United States
  • Sentara Medical Group
    Virginia Beach, Virginia 23462, United States
  • Larry D Stonesifer MD Inc PS
    Federal Way, Washington 98003, United States
  • Cedar Research
    Tacoma, Washington 98405, United States
  • Liberty Research Center
    Tacoma, Washington 98405, United States
  • Hospital Interzonal de Agudos Pedro Fiorito
    Avellaneda, Buenos Aires B1870ARG, Argentina
  • Centro Endocrinologic Tiempo
    Buenos Aires, C1117ABH, Argentina
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1181ACH, Argentina
  • Hospital Durand /Buenos Aires
    Buenos Aires, C1405CWB, Argentina
  • Hospital Gral De Agudos Dr. Teodoro Alvarez
    Buenos Aires, C1406FWY, Argentina
  • Cons Asoc de Endocrinologia
    Buenos Aires, C1425AGC, Argentina
  • Centro Medico Dra De Salvo
    Buenos Aires, C1426ABP, Argentina
  • CIMeL
    Buenos Aires, Argentina
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Sao Lucas da PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Universidade Estabual de Maringa
    Maringa Parana, 87020-900, Brazil
  • Nucleo de Medicina Integrada
    Mogi das Cruzes, 08780-090, Brazil
  • Instituto Estadual De Diabetes e Endocrinologia Luis Capriglione
    Rio de Janeiro, 20211-340, Brazil
  • Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda
    Rio de Janeiro, 22271-100, Brazil
  • Hospital Guilherme Alvaro
    Santos, 11045-904, Brazil
  • CPClin-Centro de Pesquisas Clinicas
    Sao Paulo, 01244-030, Brazil
  • Centro de Diabetes/UNIFESP-EPM
    Sao Paulo, 04020-041, Brazil
  • Blumenau Servicos Medicos S/C Ltda
    Sao Paulo, 05302-001, Brazil
  • Instituto de Pesquisa Clinica e Medicina Avancada
    Sao Paulo, 05437-010, Brazil
  • Lifestyle Metabolism Center
    Oakville, Ontario L6H 3P1, Canada
  • Lifestyle Metabolism Center
    Thornhill, Ontario L4J 8L7, Canada
  • Lifestyle Metabolism Center
    Toronto, Ontario M4R 2G4, Canada
  • Windsor Professional Research
    Windsor, Ontario N8X 3V6, Canada
  • Hospital del Salvador
    Santiago, Region Metropolitana, Chile
  • Hospital San Jose
    Santiago, 1196, Chile
  • Hospital Clinico Pontificia Universidad (009)Catolica de Chile
    Santiago, Chile
  • Hospital Padre Alberto Hurtado
    Santiago, Chile
  • Hospital San Borja ArriaranUniversidad de Chile
    Santiago, Chile
  • Instituto de Informacion de Tramiento y Educacion en Salud
    Santiago, Chile
  • Instituto Mexicano de Investigacion
    Mexico City, Durango 06700, Mexico
  • Hospital Santa Engracia-CIMA
    Garza Garcia, 66260, Mexico
  • Centro de Estudios en Diabetes
    Mexico City, 01120, Mexico
  • Hospital General de Mexico Servicio EndocrinologiaJefe Del Servicio
    Mexico City, 06726, Mexico
  • Hospital OCA-MIRC (009)
    Monterrey, 64000, Mexico
  • NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny
    Bialystok, POL 15-435, Poland
  • Katedra I Klinika Chorob Metabolicznych Collegium Medicum Uniwersytety Jagiellonskiego
    Krakow, POL 31 501, Poland
  • Instytut Centrum Zdrowia (009) Matki Polki
    Lodz, POL 93-338, Poland
  • Szpital Kolejowy im Dr w Roeflera(009) Oddzial Gastorenterologii
    Pruszkow, POL 05 800, Poland
  • Oddzial Chorob Wewnetrznych (009 Endokrynologii I Diabetologii Szpitala Wojewodzkiego
    Bialystok, 15-950, Poland

Showing the first 100 of 129 sites across 10 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jul 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 years 3 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2006
First posted
Mar 29, 2006
Start
Feb 2006
Primary completionActual
Jul 2008
CompletionActual
Aug 2008
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00308308
Responsible party
Sponsor
First posted
Mar 29, 2006
Start date
Feb 2006
Primary completion
Jul 2008
Completion
Aug 2008
Results posted
Oct 16, 2014
Last update
Oct 16, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion